Cargando…
Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51
Three prophylactic vaccines are approved to protect against HPV infections. These vaccines are highly immunogenic. The most recent HPV vaccine, Gardasil-9, protects against HPV types associated with ~90% of cervical cancer (worldwide). Thus, ~10% of HPV-associated cancers are not protected by Gardas...
Autores principales: | Yadav, Rashi, Zhai, Lukai, Kunda, Nitesh K., Muttil, Pavan, Tumban, Ebenezer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227171/ https://www.ncbi.nlm.nih.gov/pubmed/34200586 http://dx.doi.org/10.3390/v13061113 |
Ejemplares similares
-
A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2
por: Tumban, Ebenezer, et al.
Publicado: (2011) -
Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature
por: Peabody, Julianne, et al.
Publicado: (2017) -
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
por: Yadav, Rashi, et al.
Publicado: (2019) -
VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human Papillomavirus
por: Tumban, Ebenezer, et al.
Publicado: (2012) -
A Comparative Study on Delivery of Externally Attached DNA by Papillomavirus VLPs and Pseudoviruses
por: Brendle, Sarah, et al.
Publicado: (2021)